SG Americas Securities LLC Takes $210,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

SG Americas Securities LLC acquired a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,826 shares of the company’s stock, valued at approximately $210,000.

Other large investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its position in SpringWorks Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after acquiring an additional 474 shares during the period. Quantbot Technologies LP bought a new position in SpringWorks Therapeutics in the 3rd quarter worth $147,000. Quarry LP lifted its position in SpringWorks Therapeutics by 20.0% during the third quarter. Quarry LP now owns 6,000 shares of the company’s stock valued at $192,000 after purchasing an additional 1,000 shares in the last quarter. Park Avenue Securities LLC bought a new stake in SpringWorks Therapeutics during the fourth quarter valued at about $203,000. Finally, Commerce Bank purchased a new stake in SpringWorks Therapeutics in the third quarter worth about $207,000.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on SWTX shares. Wedbush reaffirmed an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, January 13th. HC Wainwright lowered their price target on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a report on Tuesday, November 12th. Evercore ISI assumed coverage on shares of SpringWorks Therapeutics in a research report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price target for the company. Finally, Guggenheim decreased their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $70.00.

SpringWorks Therapeutics Trading Up 2.5 %

NASDAQ SWTX opened at $40.28 on Friday. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $53.92. The stock has a market cap of $3.00 billion, a PE ratio of -10.38 and a beta of 0.81. The stock’s 50 day moving average is $37.88 and its 200 day moving average is $36.15.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.03. The firm had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The company’s quarterly revenue was up 4810.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. On average, analysts forecast that SpringWorks Therapeutics, Inc. will post -3.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the sale, the chief operating officer now directly owns 209,600 shares of the company’s stock, valued at approximately $8,796,912. The trade was a 8.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 7.61% of the company’s stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.